TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:13
TRINITY BIOTECH PLC ( TRIB ) https://www.trinitybiotech.com
2.02USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
TRIB
124.44%
SPY
32.74%
-38.04%
TRIB
SPY
92.93%
-29.12%
TRIB
SPY
224.41%
-87.74%
TRIB
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
81.93
122.05
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.31
1.16
12.35
-1.05
0.00
-8.04
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-24.60
10.33
-19.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.0142
-33.75
-24.30
1.54
Other Earnings and Cash Flow Stats:
TRINITY BIOTECH PLC ( TRIB ) Net Income TTM ($MM) is -45.39
TRINITY BIOTECH PLC ( TRIB ) Operating Income TTM ($MM) is -15.01
TRINITY BIOTECH PLC ( TRIB ) Owners' Earnings Annual ($MM) is -2.21
TRINITY BIOTECH PLC ( TRIB ) Current Price to Owners' Earnings ratio is -34.84
TRINITY BIOTECH PLC ( TRIB ) EBITDA TTM ($MM) is -13.09
TRINITY BIOTECH PLC ( TRIB ) EBITDA Margin is -19.82%
Capital Allocation:
TRINITY BIOTECH PLC ( TRIB ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
TRINITY BIOTECH PLC ( TRIB ) has reduced its debt by 4.872 million USD in the last 12 months
Capital Structure:
TRINITY BIOTECH PLC ( TRIB ) Interest-bearing Debt ($MM) as of last quarter is 67
TRINITY BIOTECH PLC ( TRIB ) Annual Working Capital Investments ($MM) are 15
TRINITY BIOTECH PLC ( TRIB ) Book Value ($MM) as of last quarter is 6
TRINITY BIOTECH PLC ( TRIB ) Debt/Capital as of last quarter is 1018%
Other Balance Sheet Stats:
TRINITY BIOTECH PLC ( TRIB ) has -14 million in cash on hand as of last quarter
TRINITY BIOTECH PLC ( TRIB ) has 14 million of liabilities due within 12 months, and long term debt 54 as of last quarter
TRINITY BIOTECH PLC ( TRIB ) has 38 common shares outstanding as of last quarter
TRINITY BIOTECH PLC ( TRIB ) has 0 million USD of preferred stock value
Academic Scores:
TRINITY BIOTECH PLC ( TRIB ) Altman Z-Score is 0.85 as of last quarter
TRINITY BIOTECH PLC ( TRIB ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
TRINITY BIOTECH PLC ( TRIB ) largest shareholder is CGC Financial services LLC owning 1500 shares at 0.00 ($MM) value
(an insider) shares of TRINITY BIOTECH PLC ( TRIB ) for the amount of $ on
29.29% of TRINITY BIOTECH PLC ( TRIB ) is held by insiders, and 22.62% is held by institutions
TRINITY BIOTECH PLC ( TRIB ) went public on 1995-08-18
Other TRINITY BIOTECH PLC ( TRIB ) financial metrics:
FCF:-3.44
Unlevered Free Cash Flow:-35.41
EPS:-0.94
Operating Margin:-24.60
Gross Profit Margin:10.33
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-539.36
Beta:1.54
Buffet's Owners Earnings:-2.21
Price to Owner's Earnings:-34.84
About TRINITY BIOTECH PLC ( TRIB ) :
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.